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Over the past decade, a large body of evidence has emerged demonstrating an integration of metabolic and immune response
pathways. It is now clear that obesity and associated disorders such as insulin resistance and type 2 diabetes are associated with a
metabolically driven, low-grade, chronic inﬂammatory state, referred to as “metaﬂammation.” Several inﬂammatory cytokines as
well as lipids and metabolic stress pathways can activate metaﬂammation, which targets metabolically critical organs and tissues
including adipocytes and macrophages to adversely aﬀect systemic homeostasis. On the other hand, inside the cell, fatty acid-
binding proteins (FABPs), a family of lipid chaperones, as well as endoplasmic reticulum (ER) stress, and reactive oxygen species
derived from mitochondria play signiﬁcant roles in promotion of metabolically triggered inﬂammation. Here, we discuss the
molecular and cellular basis of the roles of FABPs, especially FABP4 and FABP5, in metaﬂammation and related diseases including
obesity, diabetes, and atherosclerosis.
1.Introduction
Inﬂammation is classically characterized as heat (calor),
pain (dolor), redness (rubor), and swelling (tumor) [1].
The short-term adaptive response of inﬂammation is crucial
for integration of injury response and repair in cells and
tissues. However, the long-term consequences of prolonged
inﬂammation are often not beneﬁcial. It has recently been
shown that low-grade and chronic features of inﬂammation
are observed in metabolic diseases including obesity, insulin
resistance, type 2 diabetes, and cardiovascular disease [2, 3].
This atypical immune response emerging from metabolic
tissues is referred to as metabolically triggered inﬂammation,
“metaﬂammation,” which is principally triggered by nutri-
ents and metabolic surplus, resulting in the engagement of at
least a subset of molecules and signaling pathways involved
in classical and canonical inﬂammation [2].
A number of hormones, cytokines, and bioactive
lipids function in both metabolic and immune responses.
Metabolic and immune systems regulate each other by the
same cellular machinery. In metabolically active cells such
as adipocytes and macrophages, metaﬂammatory pathways
can be initiated by not only extracellular mediators such as
cytokines and lipids, particularly saturated fatty acids, but
also by intracellular stresses such as endoplasmic reticulum
stress and excess production of reactive oxygen species
derived from mitochondria. Signals from all of these media-
torsconvergeoninﬂammatorysignalingpathways,including
signaling kinases: c-Jun N-terminal kinase (JNK), inhibitor
ofnuclearkappaBkinase(IKK),proteinkinaseR(PKR),and
others. These pathways lead to the inhibition of insulin sig-
naling [4–6] and a vicious spiral of additional production of
inﬂammatory mediators through transcriptional regulation
using activating protein-1 (AP-1) and nuclear factor-kappa
B( N F - κB).
In this paper, we will focus on metabolically active
cell-derived fatty acid-binding proteins (FABPs), which
have been shown to regulate inﬂammatory and metabolic
responses mainly in adipocytes and macrophages, and also
discuss molecular and cellular links between FABPs and
metaﬂammation, particularly in the context of metabolic
diseases such as obesity, diabetes, and atherosclerosis.
2.FattyAcid-Binding Protein(FABP)as
a Lipid Chaperone
FABPs are a family of 14-15-kDa proteins that coordinate
lipid traﬃcking and responses in cells [7]. FABPs can2 International Journal of Inﬂammation
reversiblybindtohydrophobicligands,suchassaturatedand
unsaturated long-chain fatty acids, eicosanoids, and other
lipids,withhighaﬃnityandbroadselectivity.Todate,atleast
9d i ﬀerent FABP isoforms have been identiﬁed. Diﬀerent
members of the FABP family are expressed most abundantly
in tissues involved in active lipid metabolism. The family
contains liver (L-FABP/FABP1), intestinal (I-FABP/FABP2),
heart (H-FABP/FABP3), adipocyte (A-FABP/FABP4/aP2),
epidermal (E-FABP/FABP5/mal1), ileal (Il-FABP/FABP6),
brain (B-FABP/FABP7), myelin (M-FABP/FABP8), and
testis (T-FABP/FABP9) isoforms. FABPs have been proposed
to facilitate the transport of lipids to speciﬁc compartments
in the cell, such as to the mitochondrion or peroxisome for
oxidation, to the nucleus for lipid-mediated transcriptional
regulation, to the endoplasmic reticulum for signaling,
traﬃcking, and membrane synthesis, to cytoplasmic
enzymes for activity regulation, and to the cytoplasm for
storage as lipid droplets. However, regulatory mechanisms of
tissue-speciﬁc expression and function of various FABPs are
still poorly understood. Speciﬁc contribution of each type of
FABP to cell biology, physiology, and lipid metabolism had
not been demonstrated until FABP-deﬁcient mice models
were created.
3. Adipocyte/Macrophage FABPs
Among the FABPs, FABP4, known as adipocyte FABP (A-
FABP) or adipocyte P2 (aP2), is one of best-characterized
isoforms (Table 1). FABP4 is highly expressed in adipocytes,
making up about 1% of all soluble proteins in adipose tissue
[8]. FABP5, another FABP known as epidermal FABP (E-
FABP) or mal1, is expressed most abundantly in epidermal
cells of the skin but is also present in several other tissues and
cells including adipocytes [7]( Table 1). FABP5 constitutes
a minor fraction of FABPs in adipocytes, the amount being
about 100-fold smaller than that of FABP4 in adipocytes [9].
Thesetwoproteins,FABP4andFABP5,have52%aminoacid
similarity and bind to a variety of fatty acids with similar
selectivity and aﬃnity [10]. Interestingly, both FABP4 and
FABP5 are also expressed in macrophages and dendritic cells
[11, 12]. The stochiometry of these two proteins appears to
be approximately equal in macrophages under physiological
conditions [11]. The content of FABP4 in adipocytes is
about 10,000-fold higher than that in macrophages [13].
In a state of germline FABP4 deﬁciency, FABP5 expression
exhibits a strong compensatory increase in adipose tissue
but not in macrophages or dendritic cells [11, 12, 14]. It
has been demonstrated that both FABP4 and FABP5 play
important roles in the regulation of insulin sensitivity and
the development of atherosclerosis and that their impacts
diﬀerentially involve adipocytes or macrophages [11, 14–22].
3.1. FABP4 (A-FABP/aP2). Expression of FABP4 in adipo-
cytes is highly regulated during diﬀerentiation of adipocytes
and is transcriptionally controlled by fatty acids, peroxisome
proliferator-activated receptor (PPAR) γ agonists, dexam-
ethasone, and insulin [23–27]. Potential functional domains
ofFABP4havebeenreportedtoincludeanuclearlocalization
signal, its regulation site, and a nuclear export signal
[7, 62, 63]. The primary sequence of FABP4 does not
demonstrate a readily identiﬁable nuclear localization signal
ornuclearexportsignal.However,thesignalscouldbefound
inthetertiarystructureofFABP4.Ithasalsobeenshownthat
there is a protein-protein interaction between FABP4 and
hormone-sensitivelipase[28].Inthismodel,ithasbeenpos-
tulated that FABP4 binds to and activates hormone-sensitive
lipase in adipocytes, resulting in regulation of lipolysis.
Adipocytes in FABP4-deﬁcient mice exhibited reduced eﬃ-
ciency of lipolysis [29, 30]. Interestingly, during experimen-
tally induced lipolysis, FABP4-deﬁcient mice also revealed
reduction in insulin secretion [29]. As another protein-
protein interaction, ligand-bound FABP4 has been reported
to bind to Janus kinase 2 (JAK2) and attenuate its signaling,
indicating a new role for FABP4 as a fatty acid sensor
aﬀecting cellular metabolism [31]. It has also been reported
that phosphatase and tensin homolog on chromosome 10
(PTEN), which negatively regulates the phosphoinositide 3-
kinase pathway, interacts with FABP4, possibly regulating
of lipid metabolism and adipocyte diﬀerentiation [32].
Interestingly, PTEN-null keratinocytes showed an elevated
expression of FABP4, suggesting that PTEN plays a role in
the transcriptional regulation of FABP4 expression [55].
In the whole body metabolic phenotype, FABP4-de-
ﬁcientmiceexhibitedanincreaseinbodyweightbutreduced
insulin resistance in the context of both dietary and genetic
obesity [14, 15]. RNA interference-mediated Fabp4 germline
knockdown in mice on a high fat diet also increased body
weight and fat mass but did not signiﬁcantly aﬀect glucose
and lipid homeostasis [64], which is similar to phenotype
of the diet-induced obesity in FABP4 heterozygous knockout
mice [14] and indicates that residual FABP4 protein sustains
some elements of its function in metabolic control.
In human and mouse monocyte cell lines, FABP4
expression is induced during diﬀerentiation from monocytes
and by treatment with phorbol 12-myristate 13-acetate,
lipopolysaccharide(LPS),PPARγ agonists,andoxidizedlow-
density lipoprotein (ox-LDL) [11, 34–37]. FABP4 expression
in macrophages was also elevated by advanced glycation
end products (AGE) via engagement of the receptor for
AGE (RAGE) [38]. Conversely, a cholesterol-lowering statin,
atorvastatin, has been shown to suppress FABP4 expression
in macrophages in vitro [39]. It has also been reported
that metformin, an antidiabetic drug, inhibits forkhead box
protein O1- (FOXO1-) mediated transcription of FABP4,
leading to reduced lipid accumulation in macrophages [40].
In macrophages, FABP4 modulates cholesterol ester
accumulation and foam cell formation via inhibition of
the PPARγ-liver X receptor α (LXRα)-ATP-binding cassette
A1 (ABCA1) pathway and induces inﬂammatory responses
through activation of the IKK-NF-κB and JNK-AP-1
pathways [41, 42]. Deﬁciency of FABP4 protected against
atherosclerosis in apolipoprotein E- (ApoE-) deﬁcient mice
with or without high-cholesterol-containing western diets
[11, 16]. Bone marrow transplantation studies demon-
strated that the protective eﬀect of FABP4 deﬁciency on
atherosclerosis is predominantly related to actions in macro-
phages rather than in adipocytes [11]. FABP4 in dendritic
cells has been shown to regulate the IKK-NF-κBp a t h w a yInternational Journal of Inﬂammation 3
Table 1: Features of FABP4 and FABP5 in metaﬂammation and related diseases.
Expression Regulation and function Connection to
diseases Reference
FABP4 Adipocyte Induction by fatty acids, PPARγ agonists, dexamethazone, and insulin [23–27]
Lipolysis (interaction with HSL) [28–30]
Regulation of insulin secretion during lipolysis [29]
Fatty acid sensor (interaction with JAK2) [31]
Regulation of lipid metabolism and diﬀerentiation (interaction with
PTEN) [32]
Protection from insulin resistance and diabetes in deﬁcient mice Insulin resistance,
diabetes
[14, 15, 18,
19, 21]
Protection from insulin resistance and diabetes by a FABP4 inhibitor Insulin resistance,
diabetes [33]
Macrophage Induction by PMA, LPS, PPARγ agonists, ox-LDL, and AGE/RAGE [11, 34–38]
R e d u c t i o nb ya t o r v a s t a t i na n dm e t f o r m i n [ 39, 40]
Activation of IKK-NF-κBp a t h w a y [ 41]
Activation of JNK-AP-1 pathway [42]
Inhibition of PPARγ-LXRα-ABCA1 pathway [41]
FOXO1-mediated transcription [40]
Association with ER stress [22]
Protection from insulin resistance and diabetes in double-deﬁcient
mice∗
Insulin resistance,
diabetes [21]
Protection from atherosclerosis in deﬁcient mice Atherosclerosis [11, 16, 20]
Protection from insulin resistance and atherosclerosis by a FABP4
inhibitor
Insulin resistance,
atherosclerosis [33]
Dendritic cell Activation of IKK-NF-κBp a t h w a y [ 12]
T-cell priming [12]
Endothelial cell Expression in capillary and small vein but not in artery [43]
Regulation by VEGF-A/VEGFR2 and bFGF [43]
Induction in regenerated endothelial cells after balloon denudation of
artery [44]
Induction by intermittent hypoxia [45]
FOXO1-mediated transcription inhibited by angiopoietin-1 [46]
Expression in aortic endothelium of old ApoE-deﬁcient mice [47]
Improvement of dysfunction in aortic endothelium by a FABP4
inhibitor
Endothelial
dysfunction [47]
Association with oxidative stress and activation of NF-κB and P53
pathways Cellular senescence [48, 49]
Bronchial epithelial cell Induction by Th2 cytokines IL-4 and IL-13 [13]
Suppression by Th1 cytokine interferon γ [13]
Noninduction by PPARγ agonists [13]
Protection from asthma in deﬁcient mice Asthma [13]
Lung Detection in lung lavage cells obtained from patients Bronchopulmonary
dysplasia [50]
Detection in lung lavage cells obtained from patients Sarcoidosis [51]
Ovary Expression in granulosa cells inside atretic antral follicles [52]
Association with FABP4 gene polymorphisms Polycystic ovary
syndrome [53]4 International Journal of Inﬂammation
Table 1: Continued.
Expression Regulation and function Connection to
diseases Reference
Spleen Induction by dexamethazone [54]
T cell Induction by dexamethazone [54]
Keratinocyte Induction in PTEN-deﬁcient keratinocytes [55]
Tumor Detection in tumor Lipoblastoma,
liposarcoma [56]
Detection in tumor Urothelial
carcinoma
[57]
FABP5 Adipocyte Lipolysis [58]
Protection from insulin resistance and diabetes in deﬁcient mice Insulin resistance,
diabetes [17–19, 21]
Induction of insulin resistance in adipose-speciﬁc transgenic mice Insulin resistance,
diabetes [17]
Macrophage Regulation by TLR agonists: LPS (TLR4) and zymosan (TLR2) [59]
Induction of inﬂammatory genes, COX2 and IL-6 [60]
Protection from insulin resistance and diabetes in double-deﬁcient
mice∗
Insulin resistance,
diabetes [21]
Protection from atherosclerosis in deﬁcient mice Atherosclerosis [20, 60]
Liver Induction by a high-cholesterol diet feeding in
LDL-receptor-deﬁcient mice [61]
Others
Expression in skin, dendritic cell, tongue, mammary gland, brain,
intestine, kidney, lung, heart, skeletal muscle, testis, retina, lens, and
spleen
[7]
ABCA1: ATP-binding cassette A1; AGE: advanced glycation end products; AP-1: activating protein-1; ApoE: apolipoprotein E; bFGF: basic ﬁbroblast growth
factor; COX2: cyclooxygenase-2; ER: endoplasmic reticulum; FOXO1: forkhead box protein O1; HSL: hormone-sensitive lipase; IKK: inhibitor of nuclear
kappa B kinase; IL: interleukin; JAK2: Janus kinase 2; JNK: c-Jun N-terminal kinase; LDL: low-density lipoprotein; LPS: lipopolysaccharide; LXR: liver X
receptor; NF-κB: nuclear factor-kappa B; ox-LDL: oxidized LDL; PMA: phorbol 12-myristate 13-acetate; PPAR: peroxisome proliferator-activated receptor;
PTEN: phosphatase and tensin homolog on chromosome 10; RAGE: receptor for AGE; TLR: Toll-like receptor; VEGF-A: vascular endothelial growth factor-
A; VEGFR2: VEGF-receptor-2.
∗FABP4−/−FABP5−/− mice.
and T-cell priming [12], which might contribute to the
development of atherosclerosis since there is clear evidence
for the involvement of both dendritic and T cells in the
pathogenesis of atherosclerosis [65]. Involvement of FABP4
in atherosclerosis has also been indicated by clinical studies.
In human endarterectomy samples of carotid stenosis,
expression of FABP4 by macrophages was increased in
unstable carotid plaques [66].
3.2. FABP5 (E-FABP/mal1). Transgenic mice with adipose
tissue-speciﬁc overexpression of FABP5 exhibited enhanced
basal and hormone-stimulated lipolysis and a decrease in
insulin sensitivity in a high-fat diet model [17, 58]. Deletion
of FABP5 resulted in a mild increase in systemic insulin
sensitivity in genetic and dietary obesity mouse models [17].
Adipocytes in FABP5-deﬁcient mice showed an increased
capacity for insulin-dependent glucose transport. Except for
increased FABP3 (H-FABP) in the liver [67], there was no
compensatory increase in the expression of FABPs in tissues
including adipose tissue in FABP5-deﬁcient mice [17].
Interestingly, feeding a western-type high-cholesterol diet
increased the expression of FABP5, but not that of FABP1
(L-FABP), in liver parenchymal cells of atherosclerotic LDL-
receptor- (LDLR-) deﬁcient mice together with an increase
in plasma levels of atherogenic lipoproteins, VLDL and LDL
[61]. These observations indicate a speciﬁc role of FABP5 in
atherogenesis.
FABP5 expression in macrophages was increased by
treatment with Toll-like receptor (TLR) agonists: LPS, a
TLR4 agonist, and zymosan, a fungal product that activates
TLR2 [59]. A recent study showed that macrophage FABP5
deﬁciencysuppressedatherosclerosisinLDLR-deﬁcientmice
on a western-style diet through a reduction of the expression
of inﬂammatory genes, cyclooxygenase-2 and interleukin 6,
and macrophage recruitment in atherosclerotic lesions due
to decreased CC chemokine receptor 2 expression [60].International Journal of Inﬂammation 5
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Figure 1: Interaction of adipocytes and macrophages. FABPs, FABP4, and FABP5, in adipocytes and macrophages, are critical for regulating
inﬂammatory and metabolic responses in each type of cells and also interaction of the two types of cells.
3.3. Combined Deﬁciency of FABP4 and FABP5. Mice with
combined deﬁciency of FABP4 and FABP5 (Fabp4−/−
Fabp5−/−) on a high-fat diet or in a genetic obesity model ex-
hibit remarkably improved insulin resistance and protection
against type 2 diabetes and fatty liver disease more than
did FABP4- or FABP5-deﬁcient mice [18, 19]. Furthermore,
Fabp4−/−Fabp5−/− mice intercrossed into an ApoE-deﬁcient
atherosclerosismodeldevelopeddramaticallylessatheroscle-
rosis than that in FABP4-deﬁcient or wild-type mice on
the same background [20]. Interestingly, Fabp4−/−Fabp5−/−
Apoe−/− mice on a western-type hypercholesterolemic diet
also had a signiﬁcantly higher survival rate than that of
Apoe−/− mice, presumably due to better plaque stability and
good overall metabolic health [20].
It has recently been suggested that macrophage inﬁltra-
tion and accumulation in adipose tissue is an important
feature of metaﬂammation triggered by obesity [68, 69].
Although the impact of FABP4/FABP5 on atherosclerosis
was shown to be mainly due to actions in macrophages [11,
60], cell-based coculture experiments with adipocytes and
macrophages and bone marrow transplantation using wild-
type and Fabp4−/−Fabp5−/− mice showed that FABP actions
in both adipocytes and macrophages have distinct roles in
modulation of insulin sensitivity through inﬂammatory and
metabolicresponsesasshowninFigure 1[21].Inthissetting,
the predominant action was related to adipocyte FABPs with
a more modest contribution from macrophages.
4. Therapeutic Target for Diabetes
and Atherosclerosis
Since FABP4 and FABP5 act at the interface of metabolic
and inﬂammatory pathways and play a signiﬁcant role
in the development of insulin resistance, type 2 diabetes,
and atherosclerosis, it is expected that modiﬁcation of
the function of these FABPs may provide a new class of
multi-indication therapeutic agents. In fact, several series of
FABP4 inhibitors have recently been identiﬁed [70–75]. We
previously demonstrated that chemical inhibition of FABP4
could be a therapeutic strategy against insulin resistance,
diabetes mellitus, fatty liver disease, and atherosclerosis
in experimental models using one of the speciﬁc FABP4
inhibitors, BMS309403 [33]. This compound is an orally
active small molecule and interacts with the fatty acid-
binding pocket within the interior of FABP4 to inhibit bind-
ing of endogenous fatty acids [7, 33, 72]( Figure 2). X-ray
crystallographic studies identiﬁed the speciﬁc interactions
of BMS309403 with key residues, such as Ser53, Arg106,
Arg126, and Tyr128, within the fatty-acid-binding pocket as
thebasisofitshighinvitrobindingaﬃnityandselectivityfor
FABP4 over other FABPs [72].
The FABP4 inhibitor, BMS309403, improved glucose
metabolism and enhanced insulin sensitivity in both dietary
(high fat-fed) and genetic (ob/ob) mouse models of obesity
and diabetes [33]. Involvement of FABP4 inhibition in those
beneﬁcial eﬀects was conﬁrmed in vivo using wild-type and
Fabp4−/−Fabp5−/− mice. Although Fabp4−/− mice were not
protectedagainstfattyliverdisease, inhibition of FABP4sup-
pressed fatty liver inﬁltration, similar to the liver phenotype
of Fabp4−/−Fabp5−/− mice. One possible explanation for the
diﬀerent eﬀects between genetic deﬁciency of FABP4 and
chemical inhibition of FABP4 is that there was no compen-
satory increase in FABPs in the adipose tissue of FABP4-
inhibitor-treated mice. Furthermore, the FABP4 inhibitor
markedly reduced the extent of atherosclerotic lesions in
ApoE-deﬁcient mice [33]. Cell-based studies showed that
BMS309403 reduced macrophage foam cell formation with
decreased cholesterol ester accumulation, increased choles-
terol eﬄux, and decreased production of several inﬂamma-
tory mediators in a target tissue-speciﬁc manner [33].
In high fat-diet-induced obesity models beginning at 4
weeks of age, treatment with the FABP4 inhibitor for 4 weeks
improvedinsulinsensitivityin24-week-oldmice[33],which
had severe macrophage inﬁltration in adipose tissue, but
not in 20-week-old mice, which had much less macrophage
accumulation in adipose tissue (Furuhashi M and Hota-
misligil GS. unpublished data 2007). Recently, a similar
pattern was also found in another study in which a diﬀerent
inhibitor was not eﬀective in increasing insulin sensitivity
[75]. It is diﬃcult to completely inhibit whole FABP4 in
adipocytes because the amounts of FABP4 in adipose tissue
and adipocytes are very large [8], and these observations
therefore raise the possibility that small molecules developed
so far against FABP4 may be more eﬀective in macrophages
and hence their eﬀects in vivo may be related to the extent
of macrophage involvement with the disease process at6 International Journal of Inﬂammation
(a) (b)
Figure 2: FABP4 bound with a fatty acid or a small molecule inhibitor. (a) Human FABP4 binds to an endogenous fatty acid, palmitic
acid, as a twisted U-shaped entity in the binding pocket (PDB code: 2hnx). (b) Human FABP4 crystallized in complex with BMS309403,
a synthetic FABP4 inhibitor, is shown (PDB code: 2nnq). The molecule occupies the internal binding pocket of FABP4 and competitively
inhibits binding of endogenous fatty acids. The ﬁgures were created using PyMOL.
the stage that these molecules are tested. Undoubtedly,
future studies and alternative strategies to modulate FABP
action, alone or in combination, in disease models should
address these outstanding issues. Further studies are also
needed to determine whether chemical or other modes of
inhibition of FABP4 can be safely used in humans and to
demonstrate their eﬃcacy for metabolic diseases.
5. Ectopic Expression of FABP4
There is accumulating evidence to indicate that FABP4
is expressed in several cells other than adipocytes and
macrophages under both special and physiological condi-
tions(Table 1).Forexample,FABP4expressionwasobserved
in endothelial cells of capillaries and small veins in several
mouse and human tissues, including the heart and kidney
[43]. FABP4 was signiﬁcantly induced by treatment with
vascular endothelial growth factor-A (VEGF-A) via VEGF-
receptor-2 (VEGFR2) and by treatment with basic ﬁbroblast
growth factor (bFGF) in endothelial cells [43]. Conversely,
knockdown of FABP4 in endothelial cells reduced prolif-
eration both under baseline conditions and in response to
VEGF-A and bFGF, suggesting that FABP4 is a target of the
VEGF-A/VEGFR2 pathway and a positive regulator of cell
proliferation in endothelial cells.
Interesting observations have been reported for roles of
FABP4 in vascular injury. FABP4 was markedly upregulated
in regenerated endothelial cells obtained after endothelial
balloondenudationinvivo[44].Inhumanaorticendothelial
cells, intermittent hypoxia increased FABP4 expression [45].
Anigiopoietin-1, which participates in blood vessel stabiliza-
tion and remodeling together with angiopoietin-2, inhibited
FOXO1-mediated expression of genes including FABP4 in
endothelial cells [46]. FABP4 was expressed in the aortic
endothelium of 12-week-old ApoE-deﬁcient mice showing
endothelial dysfunction, whereas FABP4 was not detected
at the aortic endothelium in 8-week-old ApoE-deﬁcient
mice or in wild-type mice [47]. Chronic administration
of BMS309403, a small molecule FABP4 inhibitor, signiﬁ-
cantly improved endothelial dysfunction in ApoE-deﬁcient
mice [47]. Notably, recent studies have shown possible
involvement of FABP4/FABP5 in senescence of endothelial
cells [48, 49]. These observations support the notion that
pathological induction, but not physiological expression,
of FABP4 in the endothelium signiﬁcantly contributes to
pathogenesis of atherosclerosis and other types of vascular
injury.
Evidence is also accumulating as for involvement of
FABP4 in respiratory diseases. Recently, FABP4 has been
reported to be detected in lungs and bronchoalveolar
samples from patients with bronchopulmonary dysplasia
(BPD) [50]. Density of FABP4-positive endothelial cells
was increased in peribronchial blood vessels, and FABP4
was also localized in a subset of macrophages in lung
tissues. Several studies using lung lavage cells suggested that
FABP4 gene expression is responsible for pathogenesis of
sarcoidosis [51]. It is notable that expression of FABP4
in human bronchial epithelial cells is under regulation of
cytokines. FABP4 expression in bronchial epithelial cells was
enhanced by the Th2 cytokines IL-4 and IL-13, which are
involved in development of asthma, and was suppressed by
the Th1 cytokine interferon γ [13]. Interestingly, FABP4-
deﬁcient mice were protected from airway inﬂammation
independently of bone marrow-derived elements, indicating
possible protection against asthma through FABP action in
stromal cells [13]. However, it should be noted that there
are possible diﬀerences in response of FABP4 to stimuli
depending on cell types. FABP4 expression in bronchial
epithelial cells was signiﬁcantly lower than that in adipocytes
and macrophages, even after stimulation. In contrast to its
eﬀectsinadipocytesandmacrophages,PPARγ agonistscould
not induce FABP4 expression in bronchial epithelial cells.
Such tissue-speciﬁc roles and response of FABP4 need to be
taken into account for FABP4 modulating therapy.International Journal of Inﬂammation 7
In atretic antral follicles of the mouse ovary, FABP4
was detected in apoptotic granulosa cells [52], suggesting
a possible relevance to polycystic ovary syndrome (PCOS),
which often coexists with insulin resistance. Interest-
ingly, association between FABP4 gene polymorphisms and
the development of PCOS has been reported [53]. Addi-
tionally, dexamethasone treatment induced FABP4 in mouse
spleen and in cultured T lymphocytes, and its distinct
nuclear localization occurred with the dexamethasone-
induced apoptosis process [54].
FABP4 expression was also detected in lipoblasts in lipo-
blastoma and liposarcoma but not in other benign adipose
tissue or malignant connective tissue or in epithelial tumors
[56]. Moreover, FABP4 expression has been linked to human
urothelial carcinomas [57]. The signiﬁcance of these associa-
tions remains to be elucidated but points to potential utility
of FABP-based strategies to explore metabolic mechanisms
related to tumorigenesis and related therapeutic possibilities.
6.SecretionandCirculating
Concentrations of FABPs
In recent years, numerous studies have shown the presence
of FABPs in circulation. Since these cytoplasmic proteins
lack a secretory signal sequence, the presence of FABPs in
serum is considered to be a biochemical marker of tissue
injury in related cells that produce FABP proteins: FABP3
(H-FABP) for acute myocardial infarction and ongoing
myocardial damage in heart failure, FABP7 (B-FABP) for
brain injury, and FABP2 (I-FABP) for intestinal damage [76–
78]. It has recently been reported that FABP4 is detected
in serum and cultured adipocyte supernatants [79]a n d
that the serum concentration of FABP4 is associated with
obesity, type 2 diabetes, and cardiovascular diseases [79–
82]. Similar ﬁndings have also been reported for FABP5
[83, 84]. Proteomics analysis using diﬀerentiated THP-1
macrophages revealed the presence of FABP4 and FABP5 in
cell supernatants derived from macrophages [85]. However,
the mechanisms and biological correlates of extracellular
FABP4 and FABP5 remain unknown.
Serum levels of FABP4 were signiﬁcantly increased in
overweight and obese subjects compared to the level in
lean controls and were positively correlated with waist
circumference, blood pressure, and insulin resistance [79].
Similar to FABP4, circulating FABP5 levels were detected at
the level of about one tenth or less of FABP4 concentrations
and were associated with metabolic syndrome components
[83, 84]. High serum levels of FABP4 at baseline indepen-
dently predicted the development of metabolic syndrome
during a 5-year follow-up period in a Chinese popula-
tion [80]. A 10-year prospective study showed that high
FABP4 concentration at baseline was a biomarker predicting
development of type 2 diabetes, which was independent
of obesity and insulin resistance [81]. Furthermore, it has
also been reported that serum FABP4 levels are positively
correlated with carotid intima-media thickness as an index
of atherosclerosis [82]. These ﬁndings support the notion
that FABP4 is a biomarker of ongoing atherosclerosis.
Interestingly, serum levels of FABP4 could also represent
noncardiovascular pathologic processes as well. A recent
study has shown that FABP4 levels could be a novel and
obesity-independentprognosticfactorinpatientswithbreast
cancer [86].
Several drugs have been reported to modify FABP4 levels
in blood. Atorvastatin, a HMG-CoA reductase inhibitor,
and olmesartan, an angiotensin II receptor blocker, reduced
circulating FABP4 levels [87, 88], whereas pioglitazone,
an insulin-sensitizing thiazolidinedione (a PPARγ agonist),
increased FABP4 concentrations [89], which could be
explainedthroughdirectactivationofPPARγ sincethePPAR
response element is present in the FABP4 gene promoter
[90]. As general information for circulating FABPs, the
concentrations of FABPs are inﬂuenced by renal clearance
[91–93], and it might be necessary to evaluate the role of
renal dysfunction in regulation of FABP level. Future studies
should provide further insights into these phenomenon and
how they contribute to disease progression in related FABP
isoforms.
7.Lipokine
Meticulous lipidomic analyses using several samples includ-
ing adipose tissue, liver, skeletal muscle, and blood from
Fabp4−/−Fabp5−/− and wild-type mice showed markedly
increased de novo lipogenesis in adipose tissue resulting
from activation/induction of fatty acid synthase (FAS) and
stearoyl-CoA desaturase-1 (SCD-1) [94]. Consequently, an
unsaturatedfreefattyacid,palmitoleate(C16:1n7),wasiden-
tiﬁed as an adipose tissue-derived lipid hormone, referred
to as “lipokine,” that strongly suppresses hepatosteatosis
and stimulates glucose transport in skeletal muscle [94].
That study revealed a lipid-mediated endocrine network of
tissues/organs, in which adipose tissue uses lipokines such
as palmitoleate to communicate with distant organs, regu-
lating systemic metabolic homeostasis. Absence of FABP4
in macrophages also resulted in an activation of de novo
lipogenesis pathways particularly through LXRα-mediated
activation of SCD-1 [22]. This enhanced lipogenesis induced
production of bioactive lipids including palmitoleate and
resistance to ER stress. These changes also translate into
protection against atherosclerosis in mouse models [22].
Conversely, unsaturated fatty acids including palmitoleate
repressed basal and LPS-induced FABP4 expression in
macrophages via the modulation of histone deacetylation
[95].
After results of animal studies on a lipokine were
reported [94], palmitoleate in humans was examined in sev-
eral studies in the context of metabolic disease, particularly
in determining the risk for insulin resistance and type 2
diabetes. In a study that recruited 100 Caucasian subjects,
circulatingpalmitoleatewaspositivelycorrelatedwithinsulin
sensitivity assessed by euglycemic-hyperinsulinemic clamp
studies, independent of age, gender, and adiposity [96].
Another study using 3630 subjects in the US showed that
high concentrations of circulating cis isomer palmitoleate,
which is primarily produced by the liver in humans,
were associated with adiposity, carbohydrate consumption,
and alcohol use [97]. However, theassociations between8 International Journal of Inﬂammation
circulating cis palmitoleate and metabolic risk factors were
complex, perhaps related to divergent lifestyle determinants
or tissue sources of endogenous palmitoleate synthesis
from liver and adipose tissue: high fat- and carbohydrate-
containing diet and fatty liver would confound or modify
the ability to detect its metabolic eﬀects [97]. Interestingly,
it has recently been reported that circulating trans isomer
of palmitoleate, an exogenous source of C16:1n7, is asso-
ciated with markedly lower insulin resistance, higher HDL-
cholesterol level, and lower incidence of diabetes, suggesting
metabolic beneﬁts of dairy product consumption [98]. Since
this isoform is not related to endogenous production, the
relation to reduced metabolic disease points to possibilities
of the utilization of the trans isomer of palmitoleate as a
potential strategy for intervention in human diseases.
8. Concluding Remarks
FABPs, especially FABP4 and FABP5, play signiﬁcant roles
in the regulation of glucose and lipid metabolism linked to
inﬂammatory and metabolic processes through modulating
critical lipid-sensitive pathways in target cells, adipocytes,
and macrophages. There was no compromised phenotype of
FABP4- or FABP5-deﬁcient mice under normal physiologic
conditions [14, 17]. However, the mice in the context of
dietary or genetic obesity were protected from systemic
pathologic stresses such as metaﬂammation, suggesting that
the adipocyte/macrophage FABP genes may represent an
example of the “thrifty” gene hypothesis [99]. FABPs have
been evolutionarily preserved from invertebrates (lower
eukaryotes) to vertebrates including humans [100], indicat-
ing that a close and conserved link between inﬂammatory
and metabolic responses underlies the conservation of FABP
function. The presence of these FABPs may have been ben-
eﬁcial for ensuring a strong macrophage immune response
under pressure with pathogens or for maintaining adipose
tissue energy stores as part of the “thrifty” phenotype to sur-
vive in famine. Under contemporary life-style accompanied
by excessive caloric intake and decreased energy expenditure,
presence or induction of adipocyte/macrophage FABPs may
be rather disadvantageous for maintaining inﬂammatory
or metabolic homeostasis. FABPs appear to be responsible
for the development of obesity, diabetes, dyslipidemia,
and atherosclerosis, and targeting the adipocyte/macrophage
FABPs, particularly FABP4, oﬀers highly attractive therapeu-
tic opportunities for intervening metabolic derangements
as an evolutionary bottleneck in humans. Much work is
still needed to elucidate the precise biological functions of
diﬀerent forms of FABPs and to establish strategies to target
these proteins for therapeutic purposes.
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